A detailed history of Vanguard Group Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,416,321 shares of SAGE stock, worth $46.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,416,321
Previous 5,751,373 11.56%
Holding current value
$46.8 Million
Previous $108 Million 35.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$10.58 - $17.9 $7.04 Million - $11.9 Million
664,948 Added 11.56%
6,416,321 $69.7 Million
Q1 2024

May 10, 2024

BUY
$18.62 - $26.95 $8.04 Million - $11.6 Million
432,013 Added 8.12%
5,751,373 $108 Million
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $1.9 Million - $2.48 Million
111,358 Added 2.14%
5,319,360 $115 Million
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $2.94 Million - $8.6 Million
175,565 Added 3.49%
5,208,002 $107 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $2.14 Million - $3.14 Million
52,666 Added 1.06%
5,032,437 $237 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $3.51 Million - $4.39 Million
94,219 Added 1.93%
4,979,771 $209 Million
Q4 2022

Feb 10, 2023

BUY
$32.2 - $43.61 $3.15 Million - $4.26 Million
97,687 Added 2.04%
4,885,552 $186 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $1.45 Million - $1.95 Million
45,026 Added 0.95%
4,787,865 $187 Million
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $3.24 Million - $4.48 Million
117,836 Added 2.55%
4,742,839 $153 Million
Q1 2022

May 13, 2022

BUY
$30.71 - $45.71 $1.44 Million - $2.14 Million
46,762 Added 1.02%
4,625,003 $153 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $9.38 Million - $11.9 Million
-253,028 Reduced 5.24%
4,578,241 $195 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $260,039 - $370,552
6,459 Added 0.13%
4,831,269 $214 Million
Q2 2021

Aug 13, 2021

BUY
$54.88 - $79.29 $265 Million - $383 Million
4,824,810 New
4,824,810 $274 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $433M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.